GLOBAL IBS-C DRUG MARKET FORECAST 2017-2025

July 2017 | 112 pages | ID: GE002F90959EN
Inkwood Research

Abstracts

KEY FINDINGS

The global IBS-C drug market is expected to grow at a CAGR of 6.30% during the forecast period of 2017 – 2025. The major factors driving this market are:

• Modern dietary habits taking a toll on the health
• Psychological factors affecting irritable bowel syndrome
• Improved and efficient drugs in pipeline with several first-in-class molecules
• Availability of effective drugs in the market

MARKET INSIGHTS

The global IBS-C drug market is segmented on the type of drug and prescription.

Drugs type are further segmented into:

• Lubiprostone
• Linaclotide
• Stimulant Laxatives
• Osmotic Laxatives
• Others

Of these, lubiprostone is a highly popular drug in the market.

Prescription type is further segmented into:

• Prescribed
• Over the Counter

Over the counter drugs are leading this segment since no prescription from a doctor is required.

REGIONAL INSIGHTS

The global IBS-C drug market is geographically divided into the following regions:

• North America - U.S. & Canada
• Asia Pacific – China, Japan, and RoAPAC
• Europe – UK, Germany, and RoE
• Rest of World – MENA, and Latin America

Of these, the North America region is anticipated to dominate the global IBS-C drug market over the forecast period on account of its highly developed healthcare systems and advanced medical devices industry.

COMPETITIVE INSIGHTS

Some of the major players in the global IBS-C drug market are:

• Nestle
• Catalent Pharma Solutions
• Abbot Laboratories
• Sucampo Pharmaceuticals
• Synergy Pharmaceuticals
• Novartis

Contents

1. RESEARCH SCOPE

1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS

2. RESEARCH METHODOLOGY

2.1. SOURCES OF DATA
  2.1.1. SECONDARY DATA
  2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROACH
2.3. BOTTOM UP APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY

3. EXECUTIVE SUMMARY

3.1. MARKET SUMMARY

4. MARKET OVERVIEW

4.1. MARKET DEFINITION
4.2. KEY MARKET INSIGHTS
4.3. ATTRACTIVE INVESTMENT SCENARIO
4.4. POSITIONING OF KEY IBS DRUG MANUFACTURERS IN THE MARKET
4.5. DRIVERS
  4.5.1. MODERN DIETARY HABITS TAKING TOLL ON THE HEALTH
  4.5.2. PSYCHOLOGICAL FACTORS AFFECTING IRRITABLE BOWEL SYNDROME
  4.5.3. IMPROVED AND EFFICIENT DRUGS IN PIPELINE WITH SEVERAL FIRST-IN-CLASS MOLECULES
  4.5.4. IBS CAN BE A HERITABILITY ISSUE
  4.5.5. AVAILABILITY OF EFFECTIVE DRUGS IN THE MARKET
4.6. RESTRAINTS
  4.6.1. STRICT FDA REGULATIONS
  4.6.2. UNAWARENESS AND IGNORANCE AMONG PEOPLE
4.7. OPPORTUNITIES
  4.7.1. INCREASING DEMAND FOR IBS DRUGS FROM APAC MARKET
  4.7.2. HIGH UNMET NEEDS
4.8. CHALLENGES
  4.8.1. CHANGE IN LIFESTYLE AND NATURAL WAYS TO CURE IBS

5. GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2017-2025 ($ MILLION)

5.1. OVERVIEW
  5.1.1. LUBIPROSTONE
  5.1.2. LINACLOTIDE
  5.1.3. STIMULANT LAXATIVES
  5.1.4. OSMOTIC LAXATIVES
  5.1.5. OTHERS (PSYLLIUM) – QUALITATIVE INFORMATION
5.2. PIPELINE DRUG ANALYSIS: PLECANATIDE (YEAR OF LAUNCH TO 2022, $ MILLION)

6. GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)

6.1. PRESCRIBED DRUGS
  6.1.1. BRANDED IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
  6.1.2. GENERIC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
6.2. OVER THE COUNTER DRUGS

7. KEY ANALYTICS

7.1. PORTERS FIVE FORCE ANALYSIS
  7.1.1. INTENSITY OF COMPETITIVE RIVALRYOMPETITION AMONG THE
  7.1.2. BARGAINING POWER OF SUPPLIERS
  7.1.3. BARGAINING POWER OF BUYERS
  7.1.4. THREAT OF SUBSTITUTE PRODUCTS
  7.1.5. THREAT OF NEW ENTRANTS
7.2. VENDOR LANDSCAPE
7.3. OPPORTUNITY MATRIX

8. GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)

8.1. NORTH AMERICA
  8.1.1. US
  8.1.2. CANADA
8.2. EUROPE
  8.2.1. UK
  8.2.2. GERMANY
  8.2.3. REST OF THE EUROPE
8.3. ASIA PACIFIC
  8.3.1. CHINA
  8.3.2. JAPAN
  8.3.3. REST OF ASIA PACIFIC
8.4. REST OF THE WORLD
  8.4.1. MIDDLE EAST AND AFRICA
  8.4.2. LATIN AMERICA
  8.4.3. REST OF THE ROW

9. COMPANY PROFILES

9.1. CATALENT PHARMACEUTICALS SOLUTIONS
  9.1.1. OVERVIEW
  9.1.2. PRODUCT PORTFOLIO
  9.1.3. SCOT ANALYSIS
  9.1.4. STRATEGIC MOVES
9.2. NESTLE
  9.2.1. OVERVIEW
  9.2.2. PRODUCTS PORTFOLIO
  9.2.3. SCOT ANALYSIS
  9.2.4. STRATEGIC MOVES
9.3. ABBOTT LABORATORIES
  9.3.1. OVERVIEW
  9.3.2. PRODUCT PORTFOLIO
  9.3.3. SCOT ANALYSIS
  9.3.4. STRATEGIC MOVES
9.4. SYNERGY PHARMACEUTICALS
  9.4.1. OVERVIEW
  9.4.2. PRODUCTS PORTFOLIO
  9.4.3. SCOT ANALYSIS
  9.4.4. STRATEGIC MOVES
9.5. SUCAMPO PHARMACEUTICALS
  9.5.1. OVERVIEW
  9.5.2. PRODUCT PORTFOLIO
  9.5.3. SCOT ANALYSIS
  9.5.4. STRATEGIC MOVES
9.6. NOVARTIS PHARMA AG
  9.6.1. OVERVIEW
  9.6.2. PRODUCTS PORTFOLIO
  9.6.3. SCOT ANALYSIS
  9.6.4. STRATEGIC MOVES
9.7. ASTELLAS PHARMACEUTICALS
  9.7.1. OVERVIEW
  9.7.2. PRODUCT PORTFOLIO
  9.7.3. SCOT ANALYSIS
  9.7.4. STRATEGIC MOVES
9.8. ARDELYX, INC.
  9.8.1. OVERVIEW
  9.8.2. PRODUCT PORTFOLIO
  9.8.3. SCOT ANALYSIS
  9.8.4. STRATEGIC MOVES
9.9. SYNTHETIC BIOLOGICS, INC.
  9.9.1. OVERVIEW
  9.9.2. PRODUCT PORTFOLIO
  9.9.3. SCOT ANALYSIS
  9.9.4. STRATEGIC MOVES
9.10. TEVA PHARMACEUTICAL INDUSTRIES LIMITED
  9.10.1. OVERVIEW
  9.10.2. PRODUCT PORTFOLIO
  9.10.3. SCOT ANALYSIS
  9.10.4. STRATEGIC MOVES
9.11. BAMA-GEVE, SLU
  9.11.1. OVERVIEW
  9.11.2. PRODUCT PORTFOLIO
  9.11.3. SCOT ANALYSIS
9.12. FERRING BV
  9.12.1. OVERVIEW
  9.12.2. PRODUCT PORTFOLIO
  9.12.3. SCOT ANALYSIS
  9.12.4. STRATEGIC MOVES
9.13. IRONWOOD PHARMACEUTICALS, INC.
  9.13.1. OVERVIEW
  9.13.2. PRODUCT PORTFOLIO
  9.13.3. SCOT ANALYSIS
  9.13.4. STRATEGIC MOVES
9.14. SALIX PHARMACEUTICALS LTD
  9.14.1. OVERVIEW
  9.14.2. PRODUCT PORTFOLIO
  9.14.3. SCOT ANALYSIS
  9.14.4. STRATEGIC MOVES
9.15. NORGINE B.V.
  9.15.1. OVERVIEW
  9.15.2. PRODUCT PORTFOLIO
  9.15.3. SCOT ANALYSIS
  9.15.4. STRATEGIC MOVES
9.16. PROMETHEUS LABORATORIES INC.
  9.16.1. OVERVIEW
  9.16.2. PRODUCT PORTFOLIO
  9.16.3. SCOT ANALYSIS
  9.16.4. STRATEGIC MOVES
9.17. ACTAVIS NORDIC A/S
  9.17.1. OVERVIEW
  9.17.2. PRODUCT PORTFOLIO
  9.17.3. SCOT ANALYSIS
  9.17.4. STRATEGIC MOVES
9.18. ALBIREO PHARMA INC
  9.18.1. OVERVIEW
  9.18.2. PRODUCT PORTFOLIO
  9.18.3. SCOT ANALYSIS
  9.18.4. STRATEGIC MOVES
9.19. YUHAN CORP
  9.19.1. OVERVIEW
  9.19.2. PRODUCT PORTFOLIO
  9.19.3. SCOT ANALYSIS
  9.19.4. STRATEGIC MOVES
9.20. ASTRAZENECA PLC
  9.20.1. OVERVIEW
  9.20.2. PRODUCT PORTFOLIO
  9.20.3. SCOT ANALYSIS
  9.20.4. STRATEGIC MOVES
9.21. THE MENARINI GROUP
  9.21.1. OVERVIEW
  9.21.2. PRODUCT PORTFOLIO
  9.21.3. SCOT ANALYSIS
  9.21.4. STRATEGIC MOVES
9.22. ONO PHARMACEUTICAL CO., LTD.
  9.22.1. OVERVIEW
  9.22.2. PRODUCT PORTFOLIO
  9.22.3. SCOT ANALYSIS
  9.22.4. STRATEGIC MOVES

List Of Tables

LIST OF TABLES

TABLE 1 GLOBAL IBS-C MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 2 WELL KNOWN DRUGS THAT ARE PREVALENT IN IBS TREATMENT DRUG MARKET ARE
TABLE 3 IRRITABLE BOWEL SYNDROME DRUGS
TABLE 4 POPULATION OF ASIA BY AGE GROUP IN VARIOUS SUB REGION, JULY 2013
TABLE 5 GLOBAL IBS-C DRUGS MARKET BY DRUG TYPE, 2017-2025 ($ MILLION)
TABLE 6 GLOBAL LUBIPROSTONE MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 7 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 8 GLOBAL LINACLOTIDE MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 9 PRODUCT PROFILE (LINACLOTIDE)
TABLE 10 GLOBAL STIMULANT LAXATIVES MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 11 GLOBAL BISACODYL MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 12 PRODUCT PROFILE (BISACODYL)
TABLE 13 GLOBAL SENNA MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 14 PRODUCT PROFILE (SENNA)
TABLE 15 GLOBAL LACTULOSE MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 16 PRODUCT PROFILE (LACTULOSE)
TABLE 17 GLOBAL POLYETHYLENE GLYCOL MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 18 PRODUCT PROFILE (POLYETHYLENE GLYCOL)
TABLE 19 PRODUCT PROFILE (PSYLLIUM)
TABLE 20 PIPELINE PRODUCT PROFILE (PLECANATIDE)
TABLE 21 GLOBAL IBS-C DRUGS MARKET, BY PRESCRIPTION TYPE 2017-2025 ($ MILLION)
TABLE 22 GLOBAL PRESCRIBED DRUG MARKET BY REGION 2017-2025 ($ MILLION)
TABLE 23 PRODUCT PROFILE (LUBIPROSTONE)
TABLE 24 BRANDED IBS-C DRUGS MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 25 PRODUCT PROFILE (METHYL NALTREXONE BROMIDE)
TABLE 26 GENERIC IBS-C DRUG MARKET BY REGION, 2017-2025 ($ MILLION)
TABLE 27 PRODUCT PROFILE (METAMUCIL)
TABLE 28 GLOBAL OVER THE COUNTER, IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
TABLE 29 GLOBAL IBS-C DRUG MARKET BY GEOGRAPHY 2017-2025 ($ MILLION)
TABLE 30 NORTH AMERICA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
TABLE 31 EUROPE IBS-C DRUG MARKET 2017-2025 ($ MILLION)
TABLE 32 APAC IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
TABLE 33 ROW IBS-C DRUGS MARKET 2017-2025 ($ MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 GLOBAL IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 2 GLOBAL IBS-C DRUG MARKET BY DRUG TYPE 2016 & 2025 (%)
FIGURE 3 GLOBAL IBS-C DRUG MARKET BY PRESCRIPTION TYPE 2016 (%)
FIGURE 4 PREVALENCE OF IBS-C IN THE GLOBAL MARKET
FIGURE 5 DIETS RESPONSIBLE FOR IBS
FIGURE 6 PERCENTAGE OF PERSONS AGED 12 AND OVER WITH DEPRESSION BY AGE AND SEX US, 2009-2012
FIGURE 7 DRUGS PULLED OFF FROM THE MARKET
FIGURE 8 LIFESTYLE AND HOME REMEDIES FOR IBS
FIGURE 9 US IBS-C DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 10 CANADA IBS-C DRUG MARKET 2017-2025 ($ MILLION)
FIGURE 11 UK IBS-C DRUG MARKET, 2017-2025 ($ MILLION)
FIGURE 12 GERMANY IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 13 REST OF EUROPE IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 14 CHINA IBS-C DRUGS MARKET, 2017-2025, ($ MILLION)
FIGURE 15 CHINESE MEDICINE TCM TREATMENT FOR IBS
FIGURE 16 JAPAN IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
FIGURE 17 PHARMACEUTICAL MARKET SALES
FIGURE 18 REST OF APAC IBS-C DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 19 MENA IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
FIGURE 20 LATIN AMERICA IBS-C DRUGS MARKET 2017-2025, ($ MILLION)
FIGURE 21 ROW IBS-C DRUGS MARKET 2017-2025 ($ MILLION)